Seroconversion after recombinant hepatitis B vaccination

Journal of Medicine

Volumn 11, Issue 2, 2010, Pages 143-150

  Guho, Abhijit ^a   Ahad, Md Abdul ^a   Salam, Md Abdus ^a   Alim, Md Abdul ^a   Haque, Akm Enamul ^b   Islam, Quazi Tarikul ^c  

^a Khulna Medical College   (Bangladesh)

^b RAJSHAHI MEDICAL COLLEGE   (Bangladesh)

^c DHAKA MEDICAL COLLEGE   (Bangladesh)

Author keywords

Bangladesh; Hepatitis B; Hepatitis B vaccine; Seroconversion

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; SEROCONVERSION; SEX DIFFERENCE; SOCIOECONOMICS; VACCINATION; VIRUS IMMUNITY;

EID: 77955168984     PISSN: 19979797     EISSN: 20755384     Source Type: Journal    
DOI: 10.3329/jom.v11i2.5461     Document Type: Article

References (40)

1. WHO. Hepatitis B: World Health Organization Fact Sheet 204, 2000.
2. Lee WM. Hepatitis B infection. N Engl J Med 1997; 337: 1733-1745.
3. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-366.
4. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84-92.
5. Alter M. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39: S64-S69.
6. Toukan A. Strategy for the control of hepatitis B virus infection in the Middle East and North Africa. Vaccine 1990; 8(suppl): S117-S121.
7. McQuillan GM, Townsend TR, Fields HA, et al. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989; 87(suppl 3A): 5S-10S.
8. Gibney L, Saquib N, Metzger J, et al. Human immunodeficiency virus hepatitis B C and D in Bangladesh trucking industry;prevalence and risk factors. Int J Epidemiol 2001; 30: 878-884.
9. De Francisco A, Hall AJ, Alam N, et al. Hepatitis B infection in Bangladeshi mothers and infants. Southeast Asian J Trop Med Public Health 1999; 30: 296-298.
10. Rahman R, A. manullah, Sattar H, et al. Sero-epidemiological study of hepatitis B virus infection in a village. Bangladesh Med Res Counc Bull 1997; 23(2): 38-41.
11. Rumi MA, Begum K, Hasan SM, et al. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery: implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998; 59(2): 318-322.
12. Khan M, Zaki KMJ, Ahmed KU. Clinical profile: Prognostic index in hepatocellularcarcinoma. Bangladesh Med Res Coun Bull 1991; 17: 49-62.
13. Bancroft WH, Snitbhan R, Scott RM, et al.Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis 1977; 135: 79-85.
14. Scott RM, Snitbhan R, Bancroft WH, et al. Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis 1980; 142: 67-71.
15. Bowes M. American Academy of Family Physicians. Pathways of controlling Hepatitis A and B: Vaccination, Prevention and Treatment. October, 2003.
16. Siebert D and Locarnini S. Hepatitis b: issues in laboratory diagnosis and vaccination. Aust Prescr 1998; 21: 72-75.
17. Zuckermann JN. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 1996;50: 283-288.
18. Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised blind doseresponse study. Br Med J 1997; 314: 329-333.
19. Ronald W. Ellis,ed. Hepatitis B vaccine in clinical practice. New York: Marcel Dekker, 1993: 301.
20. Harpaz R, MacMohan BJ, Margolis HS. Elimination of new chronic hepatitis B virus infection: results of the Alaska immunization program. J Infect Dis 2000; 181: 413-418.
21. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescence in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 796-800.
22. Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21: 685-691.
23. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implication for policy on booster vaccination. Vaccine 1996; 14(11): 1019-1027
24. Tsebes KV, Burnett RJ, Hlungwani NP, et al. The first five years of universal hepatitis B vaccination in South Africa; evidence for elimination of HBsAg carriage in under 5-yearchildren. Vaccine 2001; 19: 3919-3926.
25. Ribeiro TM and Azevedo RS. Seroconversion of hepatitis B vaccine in infants related to the mothers serostatus in a community of Sao Jose dos Campos, state of Sao Paulo, Brazil. Clinics 2006; 61: 5.
26. Khan TM. Evaluation of immnue status against hepatitis B following Hep-B vaccination under EPI programme. 2006.
27. Craig B, Mitchell I, Anthony J, et al. Serological Hepatitis B Immunity in Vaccinated Health Care Workers. Arch Intern Med 1999; 159: 13.
28. Zeeshan. Immune response after hepatitis B vaccine in different parts of the world. BMC Infect Dis 2007; 7: 120.
29. Malay S, Tizer K, Lutwick LL. Current update of pediatric hepatitis vaccine use. Pediatr Clin North Am 2000; 47: 395-406.
30. Zaman K, Baqui AH, Yunus M, Sack RB, Chowdhury HR, Black RE. Malnutrition, cell mediated immune deficiency and acute upper respiratory tract infections in rural Bangladeshi children. Acta Paediatr 1997; 86(9): 923-927.
31. Troin F. Degos F, Brechot C, Courouce AM, Adamowicz P, Saliou P, Laplanche A, Benhamou JP, Giard M. Randomized doses: Range study of Recombinant hepatitis B vaccine Produced in Mammalian cells and Containing the S and pre S 2 sequences. J Infect Dis 1989; 160(2): 199-204
32. Ukene T, Esber H, Bessette R, Praks T, Crocker B. Site of injection and response to hepatitis B vaccine. N Eng J Med 1985; 313(9): 579-580.
33. Sharifi-Mood B, Izadi S, Salehi M, Qaedi H. Comparison of Immunogenicity of Low dose ID Hepatitis B Vaccine with Standard dose IM vaccination in Young Healthy Iranian Adults. Journal of Hepatitis Monthly 2008; 8(2): 111-114.
34. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Diestag JL, Werner BJ, Polk BF, snydman DR, Platt R, Crumpacker CS, Grady GF, Alper CA. Nonresponsiveness to hepatitis B vaccine in health care workers. Ann Inter Med 1986; 105: 356-360
35. Watanabe H, Matsuchita S, Kamikawaji N, Hirayama K, Okumura M, Sasazuki T. Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cell. Hum Immunol 1988; 22: 9-17.
36. Zucman SC, Gimenez JJ, Wambergue F, Albouze BL, Naret C, Moynot A, Jungers P, Bach JF. Distict class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998; 53: 1626-1630.
37. Atkintson WL, Pickering LK, Schwartz B et al. General recommendations on immunization. Recommendations of the advisory committee on immunization practices (ACIP) and the American Associations of Family Physicians (AAFP). MMWR Recomm Rep 2002;55: 1-35.
38. Watson JC, Hadler SC, Dykewich CA, Reef S, Philips L. Measles, mumps and rubella: vaccine use and strategies for elimination of measles rubella and congenital rubella syndrome
39. Border KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of Advisory Committee on Immunization Practices. MMWR Recomm Rep 2006; 55: 1-34
40. CDC. Protection against viral hepatitis: recommendatios of the Immunization Practices Advisory Committee (ACIP). MMWR 1990; 39: 5-22.